AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27798024 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH‐HF intervention plus usual care
Number of subjects: 50
Study 27798024 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 50
Study 24517156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (denosumab + teriparatide)
Number of subjects: 94
Study 24517156 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 94
Study 24517156 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 94
Study 22109255 — intervention group
Group type: EXPERIMENTAL
Intervention: varespladib methyl 500 mg daily
Number of subjects: 6500
Study 22109255 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6500
Study 20629489 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 microg per day)
Number of subjects: 166
Study 20629489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 17618813 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula (AVF) at the wrist for chemotherapy administration
Number of subjects: 10
Study 17618813 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy through peripheral veins without AVF (historical controls)
Number of subjects: 10
Study 15755861 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (2 mg 17beta-estradiol/d)
Number of subjects: 12
Study 15755861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (polycose)
Number of subjects: 12
Study 15755861 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 12
Study 11682423 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine 1 mg/kg combined with 50 microg/kg of morphine
Number of subjects: 50
Study 11682423 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 50 microg/kg
Number of subjects: 50
Study 9314448 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated postexposure boosters intradermally
Number of subjects: 0
Study 9314448 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccine
Number of subjects: 0
Study 8115073 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 43
Study 8115073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling
Number of subjects: 43
Study 2975227 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg
Number of subjects: 10
Study 2975227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31273513 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-based immuno-chemotherapy
Number of subjects: 18
Study 31273513 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 18
Study 28271382 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour shift (24hS)
Number of subjects: 17
Study 28271382 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-hour night shift (14hS)
Number of subjects: 17
Study 28271382 — intervention group
Group type: COMPARATOR
Intervention: Control day
Number of subjects: 17
Study 28271382 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 after 14hS
Number of subjects: 17
Study 28271382 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 after 24hS
Number of subjects: 17
Study 28271382 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-and-death emergencies
Number of subjects: 17
Study 28271382 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 17
Study 25162217 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg EFV in combination with emtricitabine/tenofovir
Number of subjects: 0
Study 25162217 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg EFV in combination with emtricitabine/tenofovir
Number of subjects: 0
Study 23129133 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP lifestyle intervention
Number of subjects: 274
Study 22372270 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartClip (SC)
Number of subjects: 40
Study 22372270 — intervention group
Group type: COMPARATOR
Intervention: In‐Ovation R (IR)
Number of subjects: 40
Study 19033020 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg sodium selenite daily
Number of subjects: 465
Study 19033020 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg sodium selenite daily
Number of subjects: 465
Study 19033020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 17066642 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surfaced microthreaded neck implants (Oneplant)
Number of subjects: 68
Study 17066642 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surfaced neck implants (Stage 1)
Number of subjects: 68
Study 17066642 — intervention group
Group type: COMPARATOR
Intervention: Machined neck implants (Ankylos)
Number of subjects: 68
Study 12895208 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline bitartrate (50 mg/kg/day)
Number of subjects: 8
Study 12895208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10875609 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor therapy
Number of subjects: 0
Study 10875609 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected patients
Number of subjects: 0
Study 10875609 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive patients at intermediate stage (CD4+ cells >150/microl)
Number of subjects: 0
Study 9437195 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg daily) and Beta-carotene (20 mg daily)
Number of subjects: 26289
Study 9437195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26289
Study 8133341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning strategies
Number of subjects: 0
Study 8133341 — intervention group
Group type: COMPARATOR
Intervention: Lecture reviewing information about diabetes
Number of subjects: 0
Study 3669070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt format (monthly reminders to self-examine)
Number of subjects: 0
Study 3669070 — intervention group
Group type: COMPARATOR
Intervention: Educational format (information on breast cancer and breast self-examinations)
Number of subjects: 0
Study 3669070 — intervention group
Group type: COMPARATOR
Intervention: Demonstration format (demonstrations and practice of examinations)
Number of subjects: 0
Study 3669070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 31542368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ITN administration
Number of subjects: 143
Study 31542368 — intervention group
Group type: COMPARATOR
Intervention: Extranasal ITN administration (control)
Number of subjects: 143
Study 31542368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ITN administration (Study 2)
Number of subjects: 143
Study 29735394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 29735394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzagliatin 75 mg once daily
Number of subjects: 258
Study 29735394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzagliatin 100 mg once daily
Number of subjects: 258
Study 29735394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzagliatin 50 mg twice daily
Number of subjects: 258
Study 29735394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzagliatin 75 mg twice daily
Number of subjects: 258
Study 27283764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (assisted in communicating their wishes to their proxy)
Number of subjects: 235
Study 27283764 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 235
Study 24169009 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 26136
Study 24169009 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 26136
Study 23422767 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (7 units) administered subcutaneously
Number of subjects: 100
Study 23422767 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 100
Study 23422767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test with insulin administration
Number of subjects: 100
Study 23422767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test without insulin administration
Number of subjects: 100
Study 20945746 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (1-SEA)
Number of subjects: 12
Study 20945746 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (2-SEA)
Number of subjects: 12
Study 20945746 — intervention group
Group type: COMPARATOR
Intervention: Both SE and S3
Number of subjects: 12
Study 18070192 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinheads (TH) lithotripter
Number of subjects: 240
Study 18070192 — intervention group
Group type: COMPARATOR
Intervention: Dornier Lithotripter S (DLS)
Number of subjects: 240
Study 16014820 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (3 days of writing about stressful events)
Number of subjects: 50
Study 16014820 — intervention group
Group type: COMPARATOR
Intervention: Control writing (writing about control topics)
Number of subjects: 50
Study 12139118 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-4 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Number of subjects: 27
Study 12139118 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-10 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Number of subjects: 27
Study 12139118 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-18 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Number of subjects: 27
Study 9823178 — intervention group
Group type: EXPERIMENTAL
Intervention: New transparent dressing
Number of subjects: 0
Study 9823178 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 0
Study 7666250 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intake manually calculated by subjects using educational materials
Number of subjects: 12
Study 7666250 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intake recalculated by authors using a computerized database
Number of subjects: 12
Study 7666250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian subjects
Number of subjects: 12
Study 2502938 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin VK 500 mg four times daily for five days
Number of subjects: 76
Study 2502938 — intervention group
Group type: COMPARATOR
Intervention: Placebo four times daily for five days
Number of subjects: 76
Study 2502938 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin VK 500 mg (compliance considered)
Number of subjects: 76
Study 2502938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (compliance considered)
Number of subjects: 76
Study 785197 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil plus radiotherapy
Number of subjects: 70
Study 785197 — intervention group
Group type: COMPARATOR
Intervention: 5‐Fluorouracil plus Imidazole Carboxamide Dimethyl Triazeno plus Vincristine plus Bis‐Chloroethyl Nitrosourea plus radiotherapy
Number of subjects: 70
Study 7261618 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31961418 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 diluted in 0.9% saline
Number of subjects: 775
Study 31961418 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 775
Study 31322735 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 280
Study 31322735 — intervention group
Group type: COMPARATOR
Intervention: Open liver resection
Number of subjects: 280
Study 28872381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sequential pneumatic compression (ISPC)
Number of subjects: 21
Study 28872381 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 21
Study 26275785 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min break in play
Number of subjects: 141
Study 26275785 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 min break in play
Number of subjects: 141
Study 26275785 — intervention group
Group type: COMPARATOR
Intervention: No break
Number of subjects: 141
Study 24122411 — intervention group
Group type: EXPERIMENTAL
Intervention: Peers encouraging
Number of subjects: 183
Study 24122411 — intervention group
Group type: COMPARATOR
Intervention: Peers present
Number of subjects: 183
Study 24122411 — intervention group
Group type: COMPARATOR
Intervention: Alone
Number of subjects: 183
Study 22921332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with Movement (MWM) and kinesiotaping (KT) techniques
Number of subjects: 20
Study 22921332 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise program
Number of subjects: 20
Study 18838485 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed virtual chromoendoscopy with the Fujinon intelligent colour enhancement (FICE) system
Number of subjects: 764
Study 18838485 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy with targeted indigocarmine chromoscopy (control group)
Number of subjects: 764
Study 17846141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin 500 mg orally four times a day for 7 days after incision and drainage
Number of subjects: 166
Study 17846141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 15221421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5% for 1 week
Number of subjects: 16
Study 15221421 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch for 12 h daily
Number of subjects: 16
Study 12516939 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir suspension 10 mg/kg
Number of subjects: 24
Study 12516939 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir suspension 20 mg/kg
Number of subjects: 24
Study 12516939 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg tablets
Number of subjects: 24
Study 12516939 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (both forms)
Number of subjects: 24
Study 9828736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg/dose four times daily (n = 18)
Number of subjects: 34
Study 9828736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 34
Study 9828736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 34
Study 7862849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (37.5-75 mg)
Number of subjects: 27
Study 7862849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 27
Study 2688064 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen, 750 mg/day for 1 week
Number of subjects: 16
Study 2688064 — intervention group
Group type: EXPERIMENTAL
Intervention: oxindanac, 600 mg/day for 1 week
Number of subjects: 16
Study 2688064 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 16
Study 2688064 — intervention group
Group type: EXPERIMENTAL
Intervention: oxindanac
Number of subjects: 16
Study 1089522 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 25
Study 1089522 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 25
Study 1089522 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocromene
Number of subjects: 25
Study 1089522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphedrine
Number of subjects: 25
Study 28728461 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual feedback-on-error
Number of subjects: 11
Study 28728461 — intervention group
Group type: COMPARATOR
Intervention: No feedback-on-error
Number of subjects: 11
Study 27721013 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity continuous training (HICT; 30 min cycling at 85% VO2max)
Number of subjects: 10
Study 27721013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT; 6 × 30 s 'all-out' cycling bouts with 4 min recovery periods)
Number of subjects: 10
Study 27721013 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL; no exercise)
Number of subjects: 10
Study 27721013 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MICT; 30 min cycling at 65% VO2max)
Number of subjects: 10
Study 27721013 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise intensities (HICT, SIT, MICT)
Number of subjects: 10
Study 25849467 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge large-bore Septoject XL needle
Number of subjects: 20
Study 25849467 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge standard-bore Septoject needle
Number of subjects: 20
Study 23064293 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg oral ephedrine
Number of subjects: 18
Study 23064293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21641868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus zoledronic acid (20 mg per day + 4 mg every 6 months)
Number of subjects: 1803
Study 21641868 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus zoledronic acid (1 mg per day + 4 mg every 6 months)
Number of subjects: 1803
Study 21641868 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (20 mg per day)
Number of subjects: 1803
Study 21641868 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole alone (1 mg per day)
Number of subjects: 1803
Study 21641868 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg every 6 months)
Number of subjects: 1803
Study 21641868 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone vs Anastrozole alone
Number of subjects: 1803
Study 21641868 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole vs Tamoxifen overall survival
Number of subjects: 1803
Study 21641868 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 1803
Study 19124803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (fluorouracil-based therapy)
Number of subjects: 20898
Study 16942532 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible-dose vardenafil (5-20 mg)
Number of subjects: 302
Study 16942532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 15254851 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian/hop extract (2 tablets)
Number of subjects: 32
Study 15254851 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian/hop extract (6 tablets)
Number of subjects: 32
Study 15254851 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (200 mg)
Number of subjects: 32
Study 15254851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11605557 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity (dim)
Number of subjects: 0
Study 11605557 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intensity stimuli
Number of subjects: 0
Study 11605557 — intervention group
Group type: COMPARATOR
Intervention: Stimulus intensity (bright)
Number of subjects: 0
Study 9537864 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadoxine (1500 mg/day)
Number of subjects: 136
Study 9537864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 7521308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin combined with IFN‐alpha
Number of subjects: 20
Study 7521308 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha alone
Number of subjects: 20
Study 2771805 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax matrix potassium chloride
Number of subjects: 0
Study 2771805 — intervention group
Group type: COMPARATOR
Intervention: Microencapsulated potassium chloride
Number of subjects: 0
Study 1020393 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapy
Number of subjects: 200
Study 30528472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg orally once daily for 6 months
Number of subjects: 3127
Study 30528472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 3127
Study 30528472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3127
Study 27363424 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 100 mg/piece
Number of subjects: 30
Study 27363424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25693137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml 0.5% isobaric bupivacaine (initial dose) adjusted by 0.1 ml based on previous outcomes
Number of subjects: 22
Study 24167059 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 7.5 mg/kg/day
Number of subjects: 26
Study 24167059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24167059 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA)
Number of subjects: 26
Study 21681226 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume exercise program (HVEP)
Number of subjects: 33
Study 21681226 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 18462246 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (150 units)
Number of subjects: 32
Study 18462246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17223806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (30 microg.kg‐1)
Number of subjects: 80
Study 17223806 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming with forced-air and intravenous midazolam (30 microg.kg‐1)
Number of subjects: 80
Study 17223806 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming with forced-air
Number of subjects: 80
Study 17223806 — intervention group
Group type: COMPARATOR
Intervention: Passive insulation and placebo
Number of subjects: 80
Study 17223806 — intervention group
Group type: COMPARATOR
Intervention: Passive insulation and intravenous midazolam (30 microg.kg‐1)
Number of subjects: 80
Study 15226332 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT)
Number of subjects: 219
Study 15226332 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 219